ArticleJournal of cancer research and clinical oncology2024
Utilization and quality of palliative care in patients with hematological and solid cancers: a population-based study.
Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Differences in perceptions of hematologists and palliative care physicians regarding transfusion therapy in patients with terminal hematological malignancies: a nationwide cross-sectional questionnaire survey in Japan.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Article
- Symptom burden and palliative care in patients with hematologic malignancies: a single-center experience.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Temporal trends and determinants of inpatient palliative care utilization among hospitalized patients with acute myeloid leukemia: a retrospective cross-sectional study.BMC palliative care · 2025Article
- Article
- Palliative care pathways in Amyotrophic Lateral Sclerosis (ALS): a sequence analysis of health claims data.BMC palliative care · 2025Article
- Lexical associations can characterize clinical documentation trends related to palliative care and metastatic cancer.Scientific reports · 2025Article
- Receipt of specialized palliative care and health care utilization at the end of life in hematological cancer patients - the Stockholm experience.Acta oncologica (Stockholm, Sweden) · 2025Observational
- Symptoms, Symptom Profiles, and Healthcare Utilization in Patients with Hematologic Malignancies: A Retrospective Observational Cohort Study and Latent Class Analysis.Current oncology (Toronto, Ont.) · 2025Observational
- End-of-life care in hematological malignancies - a nationwide comparative study on the Swedish Register of Palliative Care.PloS one · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPalliative care (PC) contributes to improved end-of-life care for patients with hematologic malignancies (HM) and solid tumors (ST) by addressing physical and psychological symptoms and spiritual needs. Research on PC in HM vs. ST patients is fragmented and suggests less use.
methodsWe analyzed claims data of all deceased members of a large German health insurance provider for the year before death. First, we analyzed the frequency and the beginning of different types of PC and compared patients with HM vs. ST. Second, we analyzed the adjusted impact of PC use on several end-of-life quality outcomes in patients with HM vs. ST. We performed simple and multiple (logistic) regression analysis, adjusted for relevant covariates, and standardized for age and sex.
resultsOf the 222,493 deceased cancer patients from 2016 to 2020, we included 209,321 in the first analysis and 165,020 in the second analysis. Patients with HM vs. ST received PC less often (40.4 vs. 55.6%) and later (34 vs. 50 days before death). PC use significantly improved all six quality indicators for good end-of-life care. HM patients had worse rates in five of the six indicators compared with ST patients. Interaction terms revealed that patients with ST derived greater benefit from PC in five of six quality indicators than those with HM.
conclusionThe data highlight the need to integrate PC more often, earlier, and more effectively into the care of patients with HM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.